A Randomized, Placebo-controlled, Single-blind, Parallel Design, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Latest Information Update: 06 Mar 2022
Price :
$35 *
At a glance
- Drugs Tertomotide (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Sponsors GemVax & KAEL
- 06 Apr 2018 Primary endpoint (Evaluation of doses of GV1001 by comparing the level of change in IPSS scores in study group 3 to a control group at week 13.) has not been met as per the results published in the BJU International.
- 06 Apr 2018 Primary endpoint (Evaluation of doses of GV1001 by comparing the level of change in IPSS scores in three study groups to a control group.) has not been met as per the results published in the BJU International.
- 06 Apr 2018 Primary endpoint (Evaluation of doses of GV1001 by comparing the level of change in IPSS scores in study groups 1 and 2 to a control group at week 13.) has been met as per the results published in the BJU International.